The 50-Dollar Pill: How Medicare’s Nod and a Three-Million-Script Blitz Are Reshaping Novo Nordisk’s Trajectory

Starting July 2026, Medicare covers Wegovy at $50/month copay, unlocking millions of seniors. Oral Wegovy hits 3M scripts in 5 months. Novo stock rebounds 40% despite cyber attack.

For more than two decades, Medicare flatly refused to cover weight-loss drugs. That wall crumbles on 1 July 2026, when the so-called Medicare GLP-1 Bridge programme goes live, letting millions of Part D beneficiaries get Wegovy — injectable or oral — for just $50 a month. The shift is so seismic that Novo Nordisk’s shares have already absorbed much of the optimism, recovering nearly 40% from their March trough of €30.25. But with the stock now technically overbought and a string of catalysts still unfolding, the real test lies in how many new patients actually step through the door.

A $245 net price unlocks a $1,000-plus market

Under the bridge programme, which runs through the end of 2027 across all US states and territories, Novo Nordisk and Eli Lilly have agreed to supply their GLP?1 medicines at a net monthly cost of $245 to Medicare — a fraction of the list prices that routinely topped $1,000. The patient co?pay is capped at $50. That alone eliminates the single biggest barrier that kept seniors from accessing Wegovy, and it transforms Novo’s addressable market overnight.

Oral Wegovy is already making history

While the Medicare news dominates headlines, the oral tablet version of Wegovy has been quietly smashing records of its own. In just over five months since its US launch, more than three million prescriptions have been written — one of the strongest pharmaceutical debuts by volume in American history. Crucially, the vast majority of those patients were new to GLP?1 therapies, meaning the pill is expanding the pool rather than cannibalising injectable sales.

International approvals are gathering pace. The United Arab Emirates has already given the green light, and Britain’s MHRA became the first European regulator to authorise the daily tablet, based on the phase?3 OASIS 4 trial. Novo plans to roll out additional launches in the second half of 2026.

Cyber attackers circle as pipelines advance

The picture is not entirely rosy. On 11 June, Novo disclosed an IT security incident in which attackers copied non?public data from internal systems, including clinical trial biomarkers and birth years — though no direct patient identifiers were compromised. Two hacker groups, FulcrumSec and TheUSERS007, claimed responsibility, demanding ransoms of $25?million and $50?million respectively. The company did not pay. Operations have continued without disruption.

Meanwhile, the pipeline carries its own weight. Novo submitted a US marketing application for CagriSema, a fixed?dose combination of cagrilintide and semaglutide, in December 2025. A decision is expected in the fourth quarter of 2026. Phase?3 data from the REIMAGINE programme, presented at the ADA congress in New Orleans and published simultaneously in The Lancet, hit all primary endpoints on HbA1c and body weight. In addition, Novo launched a new clinical trial in May for cagrilintide as a monotherapy, targeting patients who cannot tolerate oral GLP?1 therapies due to gastrointestinal side effects.

The rally has a technical warning

Novo Nordisk’s stock closed on Friday at €42.19, gaining 8.4% over the past seven trading days. That leaves the share price roughly 31% below its 52?week high of €61.20. The relative strength index has climbed to 71.3 — territory that often signals a short?term pullback. Traders are watching closely, especially with the Medicare launch providing the first real?world demand data this week.

A €11.2?billion (Danish kroner) share buyback programme, focused on B?shares, runs until February 2027, adding a floor of support.

All eyes on the 5 August numbers

On 5 August, Novo reports second?quarter results. The key metric analysts will scrutinise is the retention rate for the oral Wegovy tablet: how many patients stay on higher doses after the initial prescription burst. That figure will determine whether the record?breaking script volume translates into durable revenue — and whether the current rally has legs.